In so called DANBIO registry study, the switch from Remicade to Remsima due to non-medical reasons was investigated in a total by 802 patients with rheumatoid arthritis, psoriasis arthritis and ankylosing spondylitis. The patients were median already over 6 years on Infliximab. The switch to Remsima does not have a negative effect on the disease activity. More information about the study is available in the corresponding concise report or in the summary in German language.
DANISH SWITCHNG STUDY 2017
The results of the NorSwitch study (a switch study on the Infliximab biosimilar) confirm the safety for patients.
Find a press release and the relative commentary as PDF documents to download below.
Under the following link one can upload and view the new information booklet, developed by EMA and European Committee in relation to biosimilars:
This consensus information on biosimilar medicinal products was drafted by and for patients
together with representatives of the European Medicines Agency, the European Commission and
their stakeholders [the European Patients Forum (EPF), the European Federation of Crohn's &
Ulcerative Colitis Associations (EFCCA), the Standing Committee of European Doctors, European
Federation of Pharmaceutical Industries and Associations (EFPIA), European Association for Bioindustries
(EuropaBio) and Medicines for Europe]. The European Commission thanks Emma
Woodford (independent consultant) for the editorial and co-ordination work.
You can download the Information for patients in seven languages here: Q&A on Biosimilar Medicines